
André B Amon
@andreamonmd
🫀 M.D., Cardiologist, Echocardiography fellow @HCPA_
ID: 1593994558332981253
19-11-2022 15:48:23
85 Tweet
102 Takipçi
214 Takip Edilen

Most viewed JAMA Cardiology article: In this study, results showed that in patients with HFpEF and chronotropic incompetence, β-blocker cessation may be particularly beneficial in patients with smaller end-systolic left ventricular volume. ja.ma/3I2IruQ





Very proud of our group! Best original study award in the SBHCI 2024 meeting. We assessed the impact of a complete POCUS protocol in STEMI patients and our findings have the potential to change the paradigm of care in these patients Guilherme Teló Anderson Donelli da Silveira


Just published now! POCUS assessment in STEMI patients with a novel prognostic classification. LUV classification -> (LUS + LVOT VTI) is a better predictor of in-hospital mortality than isolated LUS assessment and killip classification. Thx Alex Truesdell for you invaluable help!


Proud of our research group with the publication of the LUV protocol, a new POCUS tool for patients with AMI combining LUS e LVOT-VTI. Eduardo R Argaiz Ana Claudia Tonelli Philippe Rola Hatem Soliman, FRCP, FEACVI, FASE, FHEA William Beaubien-Souligny NephroPOCUS Rodrigo V. Wainstein, MD, PhD Guilherme Pinheiro Machado André B Amon Anderson Donelli da Silveira






Excellent critique of the recent SUMMIT trial in Sensible Medicine by John Mandrola, MD today. Seeing more dubious endpoints being used in cardiology trials in recent years. This trend will weaken the evidence base for cardiology practice and diminish standing in the #EBM world. Do patients




